Overview
BIODLINK-B (1875)
BioDlink International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in...
- Open
- 3.370
- High
- 3.485
- Low
- 3.340
- Prev. Close
- 3.390
- Volume
- 780.00K
- Turnover
- 2.65M
- Avg Price
- 3.393
- Bid/Ask Ratio
- -92.86%
- Amplitude
- 4.28%
- 52wk High
- 5.870
- Volume Ratio
- 1.84
- Turnover Ratio
- 0.10%
- 52wk Low
- 1.700
- HK Mkt Cap
- 2.68B
- Market CapHKD
- 2.68B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.243
- EPSDynamic
- -0.174
- EPSStatic
- --
- BVPS
- 0.92
- P/B
- 3.79
- HK Shares
- 772.79M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 772.79M
- Min lot size
- 400
- Currency
- HKD
BIODLINK-B Analyst Rating
View moreForecast & Rating
Jun 5, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Jul, 3
TOT Biopharm closed up 3.45% at HKD 3.60, opening higher and touching HKD 3.71 during the morning session before retreating to a low of HKD 3.58 in the afternoon, driven by progress in parent WuXi XDC's premium takeover offer. EPS remained negative for two straight quarters with loss widening over 30x YoY, as Q4 revenue tumbled 53% to HKD 144 million and net loss expanded to HKD 58 million, while the stock still trades 38.67% below its 52-week high of HKD 5.87 yet above its 20-day MA of HKD 3.41, with YTD decline of 14%.
News
Market Movers · Biodlink climbs 6% in Hong Kong trading
Global Report · Liquidity Diverges Across HK Equities as Tech and Pharma Firms Face Shakeups
Global Report · Profit Surges and Delisting Fears: Inside Hong Kong’s Mixed Bag
Global Report · HK Earnings Diverge: CRRC Accelerates as Real Estate and Clean Energy Drag
Global Report · Space Dreams, Lithium Bets, and Cold Hard Reality in the Markets
Global Report · Structural Tensions in Hong Kong's Periphery: Navigating Cross-Border Spillovers
